CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Zoledronic Acid 5 mg/Bag 100 ml Inj +1 moredrug
Likely dose
Zoledronic Acid 5 mg/Bag 100 ml Injfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04279392
NCT04279392Phase 2Completed
CompareCT.gov

Feasibility of Bisphosphonate Use on Sleeve Gastrectomy Associated Bone Loss: Healthy Body, Healthy Bones Trial

University of Nebraska·interventional·Posted Feb 21, 2020·Updated Sep 24, 2024

In Brief

A Phase 2 clinical trial evaluating Zoledronic Acid 5 mg/Bag 100 ml Inj and Placebos for Bariatric Surgery Candidate and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

One in three adults in the United States suffers from obesity. Bariatric surgery is an increasingly utilized and effective treatment for obesity and obesity-related comorbidities, however, the massive weight loss associated with bariatric surgery adversely affects bone leads to an increased risk of fracture. Bisphosphonate medications, such as zoledronic acid, are used to treat bone loss in patients with osteoporosis, and this study investigates whether this medication can prevent bone loss associated with surgical weight loss procedures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBariatric Surgery Candidate, Bone Loss, Bone Resorption
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 21, 2020
Enrollment StartSep 1, 2020
Primary CompletionDec 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.4 years ago

Interventions

Zoledronic Acid 5 mg/Bag 100 ml Injdrug

Zoledronic acid infusion

Placebosdrug

Saline infusion